Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Research Report 2023(Status and Outlook)

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Research Report 2023(Status and Outlook)



Report Overview

CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.

There are no approved therapies to combat the debilitating symptoms of CIPN now. Current alternatives include Palliative care using antidepressants, antiepileptic drugs, or opioids, all of which have well known adverse side effects.

Americas is the largest market with about 47% market share. Europe is follower, accounting for about 27% market share.

The key players are Aptinyx Inc, Asahi Kasei Pharma Corp, Regenacy Pharmaceuticals, MAKScientific LLC, Metys Pharmaceuticals AG, Nemus Bioscience Inc, PledPharma, Sova Pharmaceuticals Inc, DermaXon LLC, Kineta Inc, Krenitsky Pharmaceuticals Inc, PeriphaGen, Apexian Pharma, WinSanTor etc.

The Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size was estimated at USD 1572.60 million in 2022 and is projected to reach USD 2427.78 million by 2029, exhibiting a CAGR of 6.40% during the forecast period.

Bosson Research’s latest report provides a deep insight into the global Chemotherapy Induced Peripheral Neuropathy Treatment market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Chemotherapy Induced Peripheral Neuropathy Treatment market in any manner.

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Aptinyx Inc

Asahi Kasei Pharma Corp

Regenacy Pharmaceuticals

MAKScientific LLC

Metys Pharmaceuticals AG

Nemus Bioscience Inc

PledPharma

Sova Pharmaceuticals Inc

DermaXon LLC

Kineta Inc

Krenitsky Pharmaceuticals Inc

PeriphaGen

Apexian Pharma

WinSanTor

Market Segmentation (by Type)

Calcium Channel α2-delta Ligands

Antidepressants

Opioids

Others

Market Segmentation (by Application)

Shallow Water

Deepwater

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Chemotherapy Induced Peripheral Neuropathy Treatment Market

Overview of the regional outlook of the Chemotherapy Induced Peripheral Neuropathy Treatment Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors


1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Chemotherapy Induced Peripheral Neuropathy Treatment
1.2 Key Market Segments
1.2.1 Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Type
1.2.2 Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
2.1 Global Market Overview
2.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (M USD) Estimates and Forecasts (2018-2029)
2.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Estimates and Forecasts (2018-2029)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Landscape
3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Manufacturers (2018-2023)
3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Manufacturers (2018-2023)
3.3 Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Manufacturers (2018-2023)
3.5 Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Sales Sites, Area Served, Product Type
3.6 Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Situation and Trends
3.6.1 Chemotherapy Induced Peripheral Neuropathy Treatment Market Concentration Rate
3.6.2 Global 5 and 10 Largest Chemotherapy Induced Peripheral Neuropathy Treatment Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Chain Analysis
4.1 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Chemotherapy Induced Peripheral Neuropathy Treatment Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Chemotherapy Induced Peripheral Neuropathy Treatment Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2018-2023)
6.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Market Share by Type (2018-2023)
6.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (2018-2023)
7 Chemotherapy Induced Peripheral Neuropathy Treatment Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Sales by Application (2018-2023)
7.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (M USD) by Application (2018-2023)
7.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate by Application (2018-2023)
8 Chemotherapy Induced Peripheral Neuropathy Treatment Market Segmentation by Region
8.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region
8.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region
8.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region
8.2 North America
8.2.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Aptinyx Inc
9.1.1 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.1.2 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.1.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.1.4 Aptinyx Inc Business Overview
9.1.5 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment SWOT Analysis
9.1.6 Aptinyx Inc Recent Developments
9.2 Asahi Kasei Pharma Corp
9.2.1 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.2.2 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.2.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.2.4 Asahi Kasei Pharma Corp Business Overview
9.2.5 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment SWOT Analysis
9.2.6 Asahi Kasei Pharma Corp Recent Developments
9.3 Regenacy Pharmaceuticals
9.3.1 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.3.2 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.3.3 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.3.4 Regenacy Pharmaceuticals Business Overview
9.3.5 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment SWOT Analysis
9.3.6 Regenacy Pharmaceuticals Recent Developments
9.4 MAKScientific LLC
9.4.1 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.4.2 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.4.3 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.4.4 MAKScientific LLC Business Overview
9.4.5 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment SWOT Analysis
9.4.6 MAKScientific LLC Recent Developments
9.5 Metys Pharmaceuticals AG
9.5.1 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.5.2 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.5.3 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.5.4 Metys Pharmaceuticals AG Business Overview
9.5.5 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment SWOT Analysis
9.5.6 Metys Pharmaceuticals AG Recent Developments
9.6 Nemus Bioscience Inc
9.6.1 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.6.2 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.6.3 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.6.4 Nemus Bioscience Inc Business Overview
9.6.5 Nemus Bioscience Inc Recent Developments
9.7 PledPharma
9.7.1 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.7.2 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.7.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.7.4 PledPharma Business Overview
9.7.5 PledPharma Recent Developments
9.8 Sova Pharmaceuticals Inc
9.8.1 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.8.2 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.8.3 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.8.4 Sova Pharmaceuticals Inc Business Overview
9.8.5 Sova Pharmaceuticals Inc Recent Developments
9.9 DermaXon LLC
9.9.1 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.9.2 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.9.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.9.4 DermaXon LLC Business Overview
9.9.5 DermaXon LLC Recent Developments
9.10 Kineta Inc
9.10.1 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.10.2 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.10.3 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.10.4 Kineta Inc Business Overview
9.10.5 Kineta Inc Recent Developments
9.11 Krenitsky Pharmaceuticals Inc
9.11.1 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.11.2 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.11.3 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.11.4 Krenitsky Pharmaceuticals Inc Business Overview
9.11.5 Krenitsky Pharmaceuticals Inc Recent Developments
9.12 PeriphaGen
9.12.1 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.12.2 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.12.3 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.12.4 PeriphaGen Business Overview
9.12.5 PeriphaGen Recent Developments
9.13 Apexian Pharma
9.13.1 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.13.2 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.13.3 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.13.4 Apexian Pharma Business Overview
9.13.5 Apexian Pharma Recent Developments
9.14 WinSanTor
9.14.1 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Basic Information
9.14.2 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product Overview
9.14.3 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Performance
9.14.4 WinSanTor Business Overview
9.14.5 WinSanTor Recent Developments
10 Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast by Region
10.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast
10.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Country
10.2.3 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Region
10.2.4 South America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Chemotherapy Induced Peripheral Neuropathy Treatment by Country
11 Forecast Market by Type and by Application (2024-2029)
11.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast by Type (2024-2029)
11.1.1 Global Forecasted Sales of Chemotherapy Induced Peripheral Neuropathy Treatment by Type (2024-2029)
11.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast by Type (2024-2029)
11.1.3 Global Forecasted Price of Chemotherapy Induced Peripheral Neuropathy Treatment by Type (2024-2029)
11.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast by Application (2024-2029)
11.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K MT) Forecast by Application
11.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (M USD) Forecast by Application (2024-2029)
12 Conclusion and Key Findings

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings